Geron (GERN) Long-Term Debt Issuances (2011 - 2021)
Geron (GERN) posted Long-Term Debt Issuances of $14.9 million for Q4 2021, up 2252.46% sequentially from -$692000.0 in Q4 2020, and up 2252.46% YoY from $633167.9 in Q4 2020.
Geron (GERN) Long-Term Debt Issuances (2011 - 2021) Analysis & Trends
Geron has reported Long-Term Debt Issuances for 3 years, with the latest figure at $14.9 million in Q4 2021.
- Quarterly Long-Term Debt Issuances rose 2252.46% year-over-year to $14.9 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $16.3 million (changed N/A YoY) and the FY2024 annual result came in at $121.1 million, up 307.81% from the prior year.
- Long-Term Debt Issuances improved to $14.9 million in Q4 2021 per GERN's latest filing, from -$692000.0 in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $14.9 million in Q4 2021 and troughed at -$692000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 14.90 Mn |
| Dec 31, 2021 | 14.90 Mn |
| Dec 31, 2020 | -692,000.00 |
| Dec 31, 2020 | -692,000.00 |
| Dec 31, 2011 | 2.14 Mn |
| Dec 31, 2011 | 2.14 Mn |